Bedrijfstakpensioenfonds Voor DE Media PNO Purchases 18,000 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bedrijfstakpensioenfonds Voor DE Media PNO increased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 31.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,000 shares of the medical device company's stock after purchasing an additional 18,000 shares during the period. DexCom makes up 1.3% of Bedrijfstakpensioenfonds Voor DE Media PNO's investment portfolio, making the stock its 28th largest holding. Bedrijfstakpensioenfonds Voor DE Media PNO's holdings in DexCom were worth $9,760,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DXCM. DSM Capital Partners LLC bought a new position in DexCom during the 4th quarter valued at $28,000. Riverview Trust Co purchased a new stake in shares of DexCom during the 1st quarter valued at $32,000. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. MV Capital Management Inc. increased its position in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after purchasing an additional 138 shares during the last quarter. Finally, Smithfield Trust Co increased its position in shares of DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DXCM traded down $13.67 during trading hours on Friday, reaching $124.34. 8,578,184 shares of the company's stock traded hands, compared to its average volume of 2,409,208. The stock has a market cap of $49.24 billion, a PE ratio of 80.22, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm's 50 day simple moving average is $131.13 and its 200-day simple moving average is $118.53. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.38% and a net margin of 16.82%. Equities analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Buying and Selling

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company's stock, valued at approximately $10,747,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 in the last quarter. 0.41% of the stock is owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several research analyst reports. UBS Group raised their target price on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 target price for the company. StockNews.com lowered DexCom from a "buy" rating to a "hold" rating in a research report on Tuesday. Citigroup lifted their price objective on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. Finally, Raymond James lifted their price objective on DexCom from $151.00 to $160.00 and gave the stock a "strong-buy" rating in a report on Friday. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus price target of $141.67.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.